RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, announced on 20 November 2026 that it repurchased 377,705 ordinary shares on 19 November 2026 at a price of $2.42 per share. The repurchased shares will be held in treasury, where they carry no voting rights, reducing the total voting rights in the company to 316,462,118. The buyback was conducted under shareholder authority granted at the June 2026 Annual General Meeting, with Jefferies International Limited acting as broker for the transaction.
Key Points
- RTW Biotech Opportunities Ltd (LSE: RTWG), managed by RTW Investments, LP
- 377,705 ordinary shares repurchased on 19 November 2026 at $2.42 per share and transferred to treasury
- Total voting rights now stand at 316,462,118; treasury shares total 29,505,322 out of 345,967,440 issued ordinary shares
- Investors should watch for further buyback activity under the existing authority, which remains valid until the 2027 AGM or earlier revocation
Buyback Executed Under June 2026 AGM Authority Permitting Up to 14.99% Repurchase
The share repurchase was conducted under authority approved by shareholders at RTW Biotech Opportunities Ltd's Annual General Meeting in June 2026, which permits the company to buy back a maximum of 14.99% of its ordinary shares. The announcement states that this authority remains in place until the next shareholder authority is granted — expected at the 2027 AGM — or until it is expressly revoked. The company confirmed that the actual number of shares repurchased will depend on prevailing market conditions, meaning the pace of future buybacks is not fixed and may vary over the remaining life of the mandate.
Treasury Share Position and Voting Rights Denominator Following 19 November Transaction
Following settlement of the 19 November 2026 transaction, RTW Biotech Opportunities Ltd's total issued ordinary share capital stands at 345,967,440 shares, of which 29,505,322 are now held in treasury. Treasury shares attract no voting rights under the company's structure. The resulting total voting rights figure of 316,462,118 is the denominator shareholders should use when calculating whether they are required to notify an interest, or a change in interest, under the FCA's Disclosure and Transparency Rules — a practical consideration for institutional investors managing threshold obligations.
No Premium to NAV Permitted and Jefferies International Appointed as Buyback Broker
The announcement confirms that the company is unable to pay a price for any ordinary shares that would equate to a premium to net asset value, a constraint directly relevant to this closed-ended investment fund structure. No maximum aggregate consideration for the buyback programme has been determined. Jefferies International Limited has been appointed as the company's broker for buyback transactions, in accordance with FCA Listing Rules. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a healthcare-focused investment firm with expertise across biopharmaceutical and medical technology sectors.
RTW Biotech Opportunities Ltd's Focus on Transformative Biopharmaceutical and Medtech Assets
RTW Biotech Opportunities Ltd is an investment fund listed on the London Stock Exchange targeting high-growth potential assets in the biopharmaceutical and medical technology sectors. The fund takes a long-term approach, backing companies developing next-generation therapies and technologies. Its investment manager, RTW Investments, LP, brings deep scientific expertise to portfolio selection. Investors may be watching whether continued buyback activity signals management's view on the relationship between the prevailing market price and the fund's underlying net asset value, given the NAV-ceiling constraint governing repurchase pricing.




Please wait processing your request...